Bank Of New York Mellon Corp Contrafect Corp Transaction History

Bank Of New York Mellon Corp

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 Feb 14, 2023	BUY	$0.09 - $0.19 $1,470 - $3,103	16,335 New	16,335 $1,000
Q2 2021 Aug 11, 2021	SELL	$3.58 - $4.9 $176,164 - $241,119	-49,208 Reduced 75.08%	16,335 $71,000
Q1 2021 May 13, 2021	SELL	$4.46 - $6.68 $15,663 - $23,460	-3,512 Reduced 5.09%	65,543 $314,000
Q4 2020 Feb 09, 2021	BUY	$5.05 - $6.4 $17,164 - $21,753	3,399 Added 5.18%	69,055 $348,000
Q3 2020 Nov 12, 2020	BUY	$5.05 - $6.99 $143,692 - $198,893	28,454 Added 76.49%	65,656 $346,000
Q2 2020 Aug 12, 2020	BUY	$4.69 - $7.81 $174,477 - $290,547	37,202 New	37,202 $237,000

49.2K

Ticker CFRX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 39,332,700
Market Cap $1.18M
Description
ContraFect Corporation, a clinical-stage biotechnology company, discovers and develops therapeutic protein and antibody products for the treatment of life-threatening and drug-resistant infectious diseases in the United States. Its lead program includes Exebacase, a lysin, which is in Phase III clinical trials for the treatment of staphylococcus...

Get notified when there are updates to the investment portfolio of Bank Of New York Mellon Corp, based on Form 13F filings with the SEC.

Stay updated on Bank Of New York Mellon Corp with notifications on news.